A Secure Healthcare Blockchain Solution for the Successful Fight Against COVID-19

By citiesabc news - Apr 18, 2020
Cologne-based blockchain company Ubirch today announced it has joined the Blockchain in Transport Alliance (BiTA), an organization dedicated to determining best practices and standards for blockchain in the transportation industry.

A Secure Healthcare Blockchain Solution for the Successful Fight Against COVID-19

News Release

CENTOGENE and Ubirch Create Secure Blockchain Solution for the Successful Fight Against COVID-19

Rostock / Cologne, Germany, April 17, 2020 ─ CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and the Cologne-based blockchain start-up Ubirch today announced a joint solution for the successful fight against the effects of SARS-CoV-2 ─ the virus causing COVID-19 ─ on the economy and social life in Germany. In the future, SARS-CoV-2 test results will be stored on the blockchain and can be retrieved at any time ─ serving as a virtual certificate of immunity to the virus. This could considerably accelerate the return to normalcy for our society and the economy.

The current contact restrictions in Germany cannot be upheld until a Coronavirus vaccine is ready for market, which has major consequences on the economy and the ability for individuals to move about freely. As it is projected that the novel virus will continue to pose a threat to society for the foreseeable future, systems will have to be adapted to include more stringent controls, increased testing efforts, the tracing of infection chains, and the isolation of potentially infected individuals as well as risk groups. In the coming weeks and months, it will likely be required for individuals to demonstrate a verified status of whether they are positive for SARS-CoV-2, or not. Such requirements are expected to apply to international flights and working in critical areas. This will be even more applicable once antibody tests are established, which will serve as reliable proof of immunity to the virus. The solution focuses on GDPR conformity: According to the highest data protection standards, user data is only stored as hash values ​​on the blockchain and cannot be interpreted without user authorization.

CENTOGENE and Ubirch have joined forces to provide a readily available and secure solution that best accelerates the transition back to our familiar economic and social coexistence. Results from SARS-CoV-2 tests performed at CENTOGENE's laboratories will be directly sealed virtually on the blockchain - similar to the way it is done at a notary in the 'real world' ─ using the Ubirch solution. Whenever an individual needs to show proof that they are not infected by the virus ─ eg, to gain access to a production plant, public transportation, or a hospital ─ the presented result can be verified with the help of a 100% genuine blockchain certificate. This form of distributed security has already proven itself in other industrial environments. The IoT-based procedure is ideally suited to secure and verify medical data.

CENTOGENE CIO Volkmar Weckesser stated, "We are convinced that only widespread testing of those currently infected with COVID-19 will bring us out of the current lockdown. For this purpose, we have developed an efficient test to screen for SARS-CoV-2 with an associated portal. Together with Ubirch's solution, the test results can be accessed everywhere in a forgery-proof manner ─ spearheading a return to normality. "

Ubirch CEO Stephan Noller said, "We are working at full speed on this new partnership, because time is of the essence, and a lot is at stake. With our joint solution, it will be possible for people to present their corona test results at any time, and thus be able to move around freely again to a large extent.
We have developed a central solution module enabling us to help swiftly lift the lockdown restrictions and move on to more targeted measures. "

Discussions are already underway with other partners ─ enabling companies to be able to quickly set up a Coronavirus tracking infrastructure in which the results of mass screenings can be used to release people from quarantine or allow them to participate fully in economic and social life again.

UBIRCH was founded in 2014, has offices in Berlin, Cologne and Munich

About Ubirch:

Ubirch is the specialist for blockchain-based technology in the field of IoT with locations in Cologne, Berlin and Munich. The team consists of experienced specialists for cryptography, blockchain and data-driven business models. Ubirch primarily addresses customers from the industry, smart cities, insurance, IoT start-ups, energy supply and logistics segments. Consisting of an extremely lightweight client for sensor firmware and the matching cloud backend, Ubirch's "Blockchain for Things" product enables data security at military grade standards and thus offers new business models for the Internet of Things. Innovative cryptography and blockchain technologies guarantee the trustworthiness of IoT data. Further information is available at www.ubirch.com

About CENTOGENE

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data and innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from approximately 500,000 patients representing over 120 different countries as of December 31, 2019, or an average of approximately 600 data points per patient .

The Company's platform includes epidemiologic, phenotypic and genetic data that reflects a global population, and also a biobank of these patients' blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners' ability to bring orphan drugs to the market. As of December 31, 2019, the Company collaborated with over 35 pharmaceutical partners for over 40 different rare diseases.

Limitless Enters ‘Smart Community’ Project To Support Rural Water Suppliers

Sep 18, 2020

CC Forum ‘Investing in Sustainable Development’ To Take Place On 24-25 September In Monaco

Sep 17, 2020

G20 Health and Finance Ministers’ Meeting: “Keep People Healthy To Keep Countries Wealthy”, Urges Think Tank

Sep 16, 2020

Interview Anndy Lian, Author, CEO and Founder of Linfinity, Bridging Blockchain Between Business & Governments 

Sep 15, 2020

Digital Transformation: COVID-19 Accelerates e-Commerce And Society 5.0 In Malaysia

Sep 14, 2020

Interview Shameer Thaha – Global Chief Strategy Officer & CEO Accubits Middle East / Africa, Building AI Blockchain Tech 

Sep 11, 2020

HealthTech: Early Cancer Detection Technology Secures £2.4M Funding Boost

Sep 10, 2020

Interview Alexander Kern, Shared Capitalism, Researcher, Managing Partner at Euro-Institute Monaco, Startups, Sustainability

Sep 09, 2020

Ravensbourne Virtual Degree Show To Showcase Students’ Best Work And Celebrate The End Of Their Time At University

Sep 08, 2020

The Great Digital-Preparedness Divide

Sep 07, 2020